Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 6Phase 1/2 4Phase 1 4Phase NA 3Phase 4 2

Status

Recruiting 3Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Breast Neoplasms 1128Carcinoma, Non-Small-Cell Lung 718Neoplasms 545Prostatic Neoplasms 502Colorectal Neoplasms 438Multiple Myeloma 336Lung Neoplasms 309Neoplasm Metastasis 288Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 245Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 171Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 161Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

enzalutamide 2cabazitaxel 2Prednisone 2Androgen Antagonists 2fludrocortisone acetate 1darolutamide 1XRP6258 1Radiosurgery 1Pluvicto 1Lutetium-177 1Lutetium 1Lenograstim 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Docetaxel 1Dexamethasone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Prostate Cancer Metastatic × Clear all
NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,310 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT04916613 2026-04-28

GETUG-AFU 40

UNICANCER

Phase 3 Recruiting
300 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting
3,360 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT03850795 2024-08-19

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hinova Pharmaceuticals USA, Inc.

Phase 3 Terminated
104 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT02961257 2022-05-12

CABASTY

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Phase 3 Completed
196 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT01254279 2015-01-21

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Sanofi

Phase 3 Completed
984 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡